Want to see JP:4934 full AI Analyst Report?
Top Page
Premier Anti-Aging Co., Ltd.
(4934)
Select Model
Select Model
Rating:53Neutral
Price Target:
¥619.00
▲(4.38% Upside)
Action:Reiterated
Date:09/15/26
The score is held back primarily by operational challenges—multi-year revenue declines, low profitability, and inconsistent cash generation—despite a resilient balance sheet with modest leverage. Technicals are mildly negative versus the 200-day trend, while valuation (P/E ~14.6) provides some support.
Positive Factors
Manageable Leverage
Low leverage and a sizable equity base reduce balance-sheet strain and provide a buffer while the company works through operational challenges. This resilience can support continued investment and help absorb weaker periods without the financial pressure associated with a highly debt-funded model.
Negative Factors
Multi-Year Revenue Contraction
Several consecutive years of revenue decline indicate ongoing demand or scale pressure rather than a single-period setback. Continued contraction can limit operating leverage, weaken the base for earnings growth, and make it harder for the company to improve profitability sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Low leverage and a sizable equity base reduce balance-sheet strain and provide a buffer while the company works through operational challenges. This resilience can support continued investment and help absorb weaker periods without the financial pressure associated with a highly debt-funded model.
Read all positive factors
Premier Anti-Aging Co., Ltd. (4934) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.12B
Dividend YieldN/A
Average Volume (3M)9.13K
Price to Earnings (P/E)14.1
Beta (1Y)0.67
Revenue Growth-14.09%
EPS Growth-22.72%
CountryJP
Employees216
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)41.74
Shares Outstanding8,720,534
10 Day Avg. Volume11,450
30 Day Avg. Volume9,133
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)0.76
Price to Sales (P/S)0.38
P/FCF Ratio40.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.1
Revenue Forecast (FY)¥14.60B
Premier Anti-Aging Co., Ltd. Business Overview & Revenue Model
Company Description
Premier Anti-Aging Co., Ltd. engages in the planning, development, import, export, mail order/EC, wholesale, and retail of cosmetics, health foods, and recovery wear in Japan. The company is involved in anti-aging and recovery businesses; and manu...
How the Company Makes Money
Premier Anti-Aging Co., Ltd. generates revenue primarily by selling its anti-aging-related products and services. Key revenue streams are expected to include (1) product sales to consumers (e.g., via direct-to-consumer channels such as online sale...
Premier Anti-Aging Co., Ltd. Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
70
Positive
Cash Flow
45
Neutral
| Breakdown | Jul 2026 | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.88B | 16.16B | 20.36B | 26.40B | 33.91B |
| Gross Profit | 10.56B | 12.39B | 16.10B | 19.24B | 26.63B |
| EBITDA | 795.00M | 916.00M | 390.00M | -423.24M | 2.50B |
| Net Income | 364.00M | 471.00M | -1.48B | -733.97M | 1.42B |
Balance Sheet | |||||
| Total Assets | 10.24B | 10.14B | 11.05B | 12.18B | 12.30B |
| Cash, Cash Equivalents and Short-Term Investments | 4.95B | 4.66B | 4.76B | 4.67B | 2.97B |
| Total Debt | 1.37B | 1.11B | 2.44B | 2.26B | 1.41B |
| Total Liabilities | 3.29B | 3.53B | 4.92B | 4.57B | 3.95B |
| Stockholders Equity | 6.96B | 6.61B | 6.12B | 7.61B | 8.35B |
Cash Flow | |||||
| Free Cash Flow | 131.00M | 1.44B | -204.00M | 2.40B | -3.35B |
| Operating Cash Flow | 217.00M | 1.47B | 425.00M | 2.42B | -3.32B |
| Investing Cash Flow | -227.00M | -229.00M | -540.00M | -900.97M | -297.68M |
| Financing Cash Flow | 267.00M | -1.34B | 183.00M | 179.77M | 501.62M |
Premier Anti-Aging Co., Ltd. Technical Analysis
Negative
593.00
Price Trends
604.04
Negative
607.63
Negative
647.36
Negative
Market Momentum
-2.80
Positive
36.71
Neutral
9.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4934, the sentiment is Negative. The current price of 593 is below the 20-day moving average (MA) of 597.05, below the 50-day MA of 604.04, and below the 200-day MA of 647.36, indicating a bearish trend. The MACD of -2.80 indicates Positive momentum. The RSI at 36.71 is Neutral, neither overbought nor oversold. The STOCH value of 9.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4934.
Premier Anti-Aging Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥6.55B | 9.62 | ― | 2.31% | 0.16% | 6.35% | |
73 Outperform | ¥1.70B | 8.80 | ― | 5.00% | -6.17% | -55.84% | |
67 Neutral | ¥40.65B | 18.17 | ― | 0.96% | 13.71% | -16.12% | |
65 Neutral | ¥5.35B | 29.17 | ― | 1.60% | 3.17% | -27.27% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
53 Neutral | ¥5.12B | 14.06 | ― | ― | -14.09% | -22.72% | |
51 Neutral | ¥7.42B | -15.15 | ― | 3.25% | -0.08% | -246.12% |
* Consumer Defensive Sector Average
JP:4934
Premier Anti-Aging Co., Ltd.
587.00
-208.00
-26.16%
JP:4918
Ivy Cosmetics Corporation
300.00
-45.62
-13.20%
JP:4925
HABA Laboratories, Inc.
1,732.00
67.82
4.08%
JP:4926
C'BON COSMETICS Co., Ltd.
1,250.00
51.94
4.34%
JP:4933
I-ne CO., LTD.
2,284.00
859.86
60.38%
JP:4936
AXXZIA, Inc.
308.00
-141.71
-31.51%
Premier Anti-Aging Co., Ltd. Corporate Events
Premier Anti-Aging Details Growth Plans and Earnings Outlook
Sep 14, 2026
Premier Anti-Aging Co., Ltd., a beauty and personal care company listed on the TSE Growth Market, operates in the anti-aging skincare segment with a focus on preventative and corrective products. It targets consumers in the expanding wellness and ...
Premier Anti-Aging Beats Forecasts but Restructuring China Unit Weighs on Bottom Line
Sep 14, 2026
Premier Anti-Aging reported that net sales and profits for the fiscal year ended July 31, 2026 modestly exceeded its June forecast, with net sales reaching ¥13.88 billion and operating profit rising to ¥494 million, aided by strong perfo...
Premier Anti-Aging Unveils FY2026 Results and FY2027 Outlook
Sep 14, 2026
Premier Anti-Aging Co., Ltd. has released its FY2026 results briefing materials, outlining company performance, segment status in anti-aging and recovery businesses, and sustainability initiatives. The company also presented its earnings forecast ...
Premier Anti-Aging Profits Slide as Sales Decline and Outlook Remains Cautious
Sep 14, 2026
Premier Anti-Aging reported a 14.1% decline in net sales to ¥13.88 billion for the year ended July 31, 2026, with operating profit down 19.8% to ¥494 million and profit attributable to owners of parent falling 22.8% to ¥364 million....
Premier Anti-Aging Restructures China Operations, Shuts Shanghai Subsidiary
Jul 17, 2026
Premier Anti-Aging Co., Ltd. has decided to dissolve and liquidate its consolidated subsidiary Premier Anti-Aging (Shanghai) Co., Ltd. as part of a structural reform of its China operations. The move reflects a strategic shift in how the company m...
Premier Anti-Aging to Liquidate Loss-Making China Subsidiary and Pivot to Cross-Border E-Commerce
Jul 14, 2026
Premier Anti-Aging Co., Ltd. has resolved to dissolve and liquidate its wholly owned Chinese subsidiary, Premier Anti-Aging (Shanghai) Co., Ltd., as part of a structural reform of its operations in China. The Shanghai unit, established in 2021 to ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.